Uveitis associated with juvenile idiopathic arthritis

@article{Sen2015UveitisAW,
  title={Uveitis associated with juvenile idiopathic arthritis},
  author={Ethan S Sen and Andrew D. Dick and Athimalaipet V. Ramanan},
  journal={Nature Reviews Rheumatology},
  year={2015},
  volume={11},
  pages={338-348}
}
Uveitis is a potentially sight-threatening complication of juvenile idiopathic arthritis (JIA). JIA-associated uveitis is recognized to have an autoimmune aetiology characterized by activation of CD4+ T cells, but the underlying mechanisms might overlap with those of autoinflammatory conditions involving activation of innate immunity. As no animal model recapitulates all the features of JIA-associated uveitis, questions remain regarding its pathogenesis. The most common form of JIA-associated… Expand
Juvenile idiopathic arthritis-associated uveitis.
TLDR
A recently published randomised controlled trial of adalimumab in JIA-associated uveitis now provides convincing evidence for the use of this biologic in patients who fail to respond adequately to methotrexate. Expand
Juvenile idiopathic arthritis-associated uveitis.
TLDR
Two randomised controlled trials of adalimumab in JIA-associated uveitis provide convincing evidence for the use of this biologic in patients who fail to respond adequately to methotrexate. Expand
Juvenile idiopathic arthritis-associated uveitis
TLDR
The epidemiology of JIA-associated uveitis, the underlying pathogenesis and how affected patients may present are highlighted, along with the current guidelines and criteria for screening, diagnosis and monitoring. Expand
Therapeutic advances in juvenile idiopathic arthritis - associated uveitis
Purpose of review The aim of this review is to highlight recent changes in the treatment of juvenile idiopathic arthritis (JIA) – associated uveitis in the era of biologics. Recent findings EarlyExpand
Uveitis in Children
TLDR
Initial treatment of JIA-associated uveitis is with topical steroids but there is increasing evidence for earlier introduction of systemic immunosuppressive drugs, such as methotrexate, as steroid-sparing agents. Expand
Adalimumab for childhood onset uveitis
TLDR
This small study provides further support for the use of adalimumab in childhood uveitis with a reduction of at least 30% of ocular inflammation on LFP with no worsening of anterior chamber cells or flare according to Standardised Uveitis Nomenclature criteria. Expand
Impact of Juvenile Idiopathic Arthritis Associated Uveitis in Early Adulthood
TLDR
Bilateral visual outcome in early adulthood in patients with JIA-uveitis appears to be fairly good, although one third of the patients developed one visually impaired or blind eye. Expand
Juvenile Idiopathic Arthritis
TLDR
Early and aggressive therapy can result in normal childhoods for children with JIA, with dramatic reduction in cases of blindness resulting from uveitis. Expand
Complication and prognosis of juvenile idiopathic arthritis associated uveitis in the era of modern immunomodulatory treatment.
TLDR
Screening for JIA-U in all JIA patients and early treatment is of prime importance, as it is still associated with high risk of late sequelae and visual acuity loss, functionally and structurally eye damage and quality of life impairment. Expand
Frequency and Identification of Risk Factors of Uveitis in Juvenile Idiopathic Arthritis
  • G. Conti, V. Chirico, +5 authors C. Fede
  • Medicine
  • Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • 2019
TLDR
Patients with early-onset ANA-positive oligoarticular JIA have the highest risk of developing uveitis, and a routine ophthalmological follow-up is required at regular intervals, even though the joint disease is clinically quiescent. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 129 REFERENCES
Juvenile idiopathic arthritis-associated uveitis
TLDR
JIA-associated uveitis carries significant ocular morbidity that lasts well into adulthood, and treatment with immunosuppressive agents can reduce the risk of ocular complications. Expand
Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis
TLDR
Cases of refractory JIA-associated uveitis treated with Golimumab, a novel fully humanized anti-TNFα monoclonal antibody that has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis are presented. Expand
Current therapeutic approaches to autoimmune chronic uveitis in children.
TLDR
A step-by-step approach to the use of immunosuppressants in this context is suggested and an anti-inflammatory therapy based on an immuno-modulatory approach seems a reasonable strategy for non-infectious chronic uveitis, in children as well as in adults. Expand
Pathogenesis of juvenile idiopathic arthritis associated uveitis: the known and unknown.
TLDR
The possible role of immune responses and cytokine involvement, genetic associations, and the influence of external triggers in this disease are discussed and an association that is supported by data obtained from arthritis research and experimental uveitis models is discussed. Expand
Tocilizumab for Severe Chronic Anterior Uveitis Associated with Juvenile Idiopathic Arthritis in a Pediatric Patient
TLDR
One case of anterior nongranulomatous uveitis in a pediatric patient refractory to anti-TNF therapy who responded favorably to tocilizumab (TCZ), a monoclonal antibody against the interleukin-6 receptor (IL-6) is presented. Expand
Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis
TLDR
Abatacept is a promising alternative treatment in refractory cases of JIA uveitis but may not be as successful in controlling joint disease. Expand
Pathophysiology of JIA-associated Uveitis
TLDR
With advancing technology and advancing knowledge of the underlying mechanisms of JIA-associated uveitis, new targets for therapy might evolve in the coming years. Expand
Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis
TLDR
Collaboration between pediatric rheumatologists and ophthalmologists is important for the successful diagnosis and treatment of patients with uveitis associated with JIA. Expand
Is Tocilizumab an Effective Option for Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis?
TLDR
There is a significant need for patients with JIA patients with uveitis who do not respond properly to the widely used disease-modifying antirheumatic drugs (DMARD), including tumor necrosis factor-α (TNF-α) inhibitors, to be treated with Tocilizumab. Expand
Review for Disease of the Year: Epidemiology of Juvenile Idiopathic Arthritis and its Associated Uveitis: The Probable Risk Factors
TLDR
For improvement of epidemiological knowledge of this complicated disease, large, well-defined, long-term population-based registries are needed with the application of universally agreed case definitions and outcome measures. Expand
...
1
2
3
4
5
...